Virus Filtration Market Report 2026

The virus filtration market size has grown rapidly in recent years. It will grow from $5.94 billion in 2025 to $6.68 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to growth in biologics manufacturing, regulatory focus on viral safety, expansion of vaccine production, increased outsourcing to CROs, adoption of advanced filtration technologies.

The virus filtration market size is expected to see rapid growth in the next few years. It will grow to $10.81 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growth in cell and gene therapies, expansion of biomanufacturing capacity, stricter regulatory standards, rising biologics pipeline, demand for contamination free production. Major trends in the forecast period include rising demand for biopharmaceutical safety, expansion of gene and cell therapy manufacturing, growing adoption of single use filtration systems, increased focus on process validation, rising use in vaccine production.

The increasing number of chronic diseases is expected to support the growth of the virus filtration market. Chronic diseases are long-term conditions that require ongoing medical attention or limit daily activities. Virus filtration helps reduce the risk of infectious and chronic diseases by effectively removing viruses during the production of biological and medical products. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research organization, reported that more than half a billion people worldwide were living with diabetes, with projections indicating the number could rise to 1.3 billion by 2050. Therefore, the growing prevalence of chronic diseases is driving demand for virus filtration technologies.

The increasing demand within the pharmaceutical industry is also expected to drive the virus filtration market. The pharmaceutical industry conducts research, development, production, and marketing of medications and therapies. Virus filtration plays a crucial role in manufacturing biopharmaceuticals, vaccines, and advanced therapies, ensuring that products are safe, effective, and free from viral contaminants. For instance, in May 2024, IQVIA Inc., a US-based pharmaceutical analytics company, reported that U.S. medicine spending reached $435 billion at net price levels in 2023. By 2028, net spending is projected to grow by $127 billion, driven by increased medicine usage and adoption of innovative therapies, though partially offset by lower prices resulting from patent expiries and regulatory changes. Therefore, the growing pharmaceutical sector is contributing to the expansion of the virus filtration market.

Major companies in the virus filtration market are focusing on next-generation high-flux filtration technologies to improve bioprocess efficiency, increase throughput, and maintain robust viral safety. High-flux filtration allows liquids to pass through membranes at faster rates while preserving separation performance, reducing processing time and improving productivity. For example, in October 2024, Asahi Kasei Medical, a Japan-based chemical company, introduced Planova FG1, a next-generation virus removal filter aimed at improving biopharmaceutical manufacturing efficiency. Planova FG1 provides approximately seven times higher flux than the company’s BioEX model, significantly reducing filtration time while maintaining strong viral removal performance - even during process interruptions. Early evaluations showed high protein recovery and consistent results without requiring prefiltration. Designed to be compatible with standard CIP and SIP systems, FG1 integrates easily into existing production setups. The product line will continue to expand to support rising global demand for biopharmaceuticals.

Major companies operating in the virus filtration market are Merck & Company Inc., GE Healthcare, Thermo Fisher Scientific Inc., Lonza Group Ltd., Pall Corporation, Charles River Laboratories International Inc., Sartorius AG, Asahi Kasei Medical Co. Ltd., WuXi AppTec, Danaher Corporation, Sigma-Aldrich Corporation, Pendotech, Purafil Inc., Parker Hannifin Corporation, Eaton Corporation, Freudenberg Group, Entegris Inc., Meissner Filtration Products Inc., Koch Membrane Systems Inc., Graver Technologies LLC, Amazon Filters Ltd., Cobetter Filtration Equipment Co. Ltd., Sterlitech Corporation, Membrane Solutions LLC, Advantec MFS Inc., GVS Group, Porvair Filtration Group.

North America was the largest region in the virus filtration market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virus filtration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the virus filtration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The virus filtration market consists of revenues earned by entities by providing virus filtering services to effectively remove viruses in various processes. The market value includes the value of related goods sold by the service provider or included within the service offering. The virus filtration market also includes sales of filters and systems used to remove viruses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.